Switch theme
Sign up to access all valuation multiples
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin’s largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).
1968
3.3K+
LTM Revenue $1.4B
LTM EBITDA $457M
$6.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diasorin has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of $457M.
In the most recent fiscal year, Diasorin achieved revenue of $1.3B and an EBITDA of $448M.
Diasorin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diasorin valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Profit | $1.4B | XXX | $878M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $457M | XXX | $448M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $338M | XXX | $298M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $222M | XXX | $211M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $666M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Diasorin's stock price is EUR 91 (or $103).
Diasorin has current market cap of EUR 4.9B (or $5.5B), and EV of EUR 5.6B (or $6.3B).
See Diasorin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.3B | $5.5B | XXX | XXX | XXX | XXX | $4.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Diasorin has market cap of $5.5B and EV of $6.3B.
Diasorin's trades at 4.7x EV/Revenue multiple, and 14.0x EV/EBITDA.
Equity research analysts estimate Diasorin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Diasorin has a P/E ratio of 25.0x.
See valuation multiples for Diasorin and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.5B | XXX | $5.5B | XXX | XXX | XXX |
| EV (current) | $6.3B | XXX | $6.3B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | 13.8x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | 18.6x | XXX | 21.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.0x | XXX | 26.2x | XXX | XXX | XXX |
| EV/FCF | 24.3x | XXX | 23.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiasorin's last 12 month revenue growth is 7%
Diasorin's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Diasorin's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Diasorin's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Diasorin and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diasorin acquired XXX companies to date.
Last acquisition by Diasorin was XXXXXXXX, XXXXX XXXXX XXXXXX . Diasorin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Diasorin founded? | Diasorin was founded in 1968. |
| Where is Diasorin headquartered? | Diasorin is headquartered in Italy. |
| How many employees does Diasorin have? | As of today, Diasorin has 3.3K+ employees. |
| Who is the CEO of Diasorin? | Diasorin's CEO is Mr. Carlo Rosa. |
| Is Diasorin publicy listed? | Yes, Diasorin is a public company listed on MIL. |
| What is the stock symbol of Diasorin? | Diasorin trades under DIA ticker. |
| When did Diasorin go public? | Diasorin went public in 2007. |
| Who are competitors of Diasorin? | Similar companies to Diasorin include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of Diasorin? | Diasorin's current market cap is $5.5B |
| What is the current revenue of Diasorin? | Diasorin's last 12 months revenue is $1.4B. |
| What is the current revenue growth of Diasorin? | Diasorin revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Diasorin? | Current revenue multiple of Diasorin is 4.6x. |
| Is Diasorin profitable? | Yes, Diasorin is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Diasorin? | Diasorin's last 12 months EBITDA is $457M. |
| What is Diasorin's EBITDA margin? | Diasorin's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Diasorin? | Current EBITDA multiple of Diasorin is 13.8x. |
| What is the current FCF of Diasorin? | Diasorin's last 12 months FCF is $259M. |
| What is Diasorin's FCF margin? | Diasorin's last 12 months FCF margin is 19%. |
| What is the current EV/FCF multiple of Diasorin? | Current FCF multiple of Diasorin is 24.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
